This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 12, 2013 /PRNewswire-USNewswire/ --
Robert J. Hugin, chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were
Ian C. Read, president and CEO of Pfizer Inc, as chairman-elect of the PhRMA Board of Directors, and
Kenneth C. Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board treasurer.
Mr. Hugin succeeds
John C. Lechleiter, Ph.D., chairman, president, and CEO of Eli Lilly and Company, as PhRMA's chairman.
John Lechleiter's tireless leadership over the past year has helped to reinvigorate the biopharmaceutical research sector at a time when a challenging public policy environment threatens to put America's global leadership in medical innovation at risk," said PhRMA President and CEO
John J. Castellani. "As Bob Hugin assumes the chairmanship, I know he will continue to emphasize the importance of patient-centered policies that properly value medicines, incentivize innovation and provide a strong foundation for the millions of U.S. jobs our industry creates and supports."
Mr. Hugin became CEO of Celgene Corporation in June of 2010 having served as president and chief operating officer since
May 2006. In
June 2011, the Celgene Board of Directors elected Mr. Hugin chairman. He was instrumental in the strategic growth of the company, overseeing the expansion of Celgene from a U.S.-based biopharmaceutical company to a global company with operations in more than 50 countries located in the Americas,
Japan and the
Asia-Pacific region. He joined Celgene as senior vice president and chief financial officer in
June 1999 and was elected to the Board of Directors in
"I look forward to working with our leadership team, the PhRMA staff, and our member companies to advocate for policies that support the advancement of medical innovation and that ensure access for patients to life-extending therapies," Mr. Hugin said. "Through our actions, we must ensure that continued medical innovation is part of the solution to healthcare costs and economic growth in the long term."